Fatty Acid Oxidation Disorder Market Size & Share, by Type (Long Chain, Short Chain), End User (Hospitals, Clinics, Pharmaceutical Companies) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5403
  • Published Date: Nov 27, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Fatty Acid Oxidation Disorder Market size is anticipated to reach USD 20 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of fatty acid oxidation disorder was over USD 10 Billion. The integration of telehealth services is one of the main growth drivers fueling the market. Telehealth can address the challenge of geographical disparities in access to specialized healthcare for individuals with FAODs. Patients residing in remote or underserved areas often face difficulties in accessing expert clinicians and metabolic disorder centers. By integrating telehealth services, healthcare providers can extend their reach to a broader patient population, ensuring timely consultations and follow-ups. According to a study, the use of telehealth services for chronic disease management led to a 25% reduction in hospitalizations and a 19% reduction in emergency department visits, emphasizing the positive impact on healthcare utilization.

Fatty acid oxidation disorders (FAODs) are a group of rare genetic metabolic disorders characterized by the body's inability to break down certain fats and convert them into energy. This results in a buildup of fatty acids in various tissues and organs, leading to a range of symptoms and complications. Supportive regulatory frameworks that facilitate the development and approval of treatments for rare diseases, including FAODs, can contribute to the growth of the market.


Fatty Acid Oxidation Disorder Market Overview
Get more information on this report: Request Free Sample PDF


Fatty Acid Oxidation Disorder Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~8%

Base Year Market Size (2023)

~ USD 10 Billion

Forecast Year Market Size (2036)

~ USD 20 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Fatty Acid Oxidation Disorder Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Increased Awareness and Early Diagnosis: Early diagnosis of FAODs is crucial for improving patient outcomes. These disorders often manifest with nonspecific symptoms, and delayed diagnosis can lead to severe complications. A study published in the Journal of Inherited Metabolic Disease emphasizes the impact of delayed diagnosis on morbidity and mortality in FAODs. Many countries are expanding their newborn screening panels to include a broader range of genetic disorders, including FAODs. This expansion has been supported by organizations like the World Health Organization (WHO) and the American College of Medical Genetics and Genomics (ACMG).
  • Advancements in Genetic Testing: Genetic testing plays a pivotal role in confirming FAOD diagnoses and guiding personalized treatment plans. The development of next-generation sequencing technologies has revolutionized genetic testing, making it more accurate and efficient. Molecular genetic testing allows for the identification of specific genetic mutations associated with FAODs. Advancements in technology have led to a reduction in the cost of genetic testing. Increased accessibility contributes to the early identification of affected individuals and facilitates timely intervention.
  • Regulatory Support: Supportive regulatory frameworks are essential for the development and approval of treatments for rare diseases, including FAODs. The Orphan Drug Act, enacted in 1983, provides critical regulatory support, encouraging pharmaceutical companies to pursue research in this field. The FDA's Rare Diseases Program emphasizes patient-focused drug development, engaging with stakeholders to gather patient perspectives and incorporate them into the regulatory decision-making process.

Challenges

  • Clinical Heterogeneity: FAODs exhibit clinical heterogeneity, meaning that the severity and presentation of symptoms can vary widely among affected individuals. This heterogeneity poses challenges in establishing standardized diagnostic criteria and treatment protocols. Tailoring interventions to individual needs is essential. Research efforts must focus on understanding the underlying genetic and biochemical factors contributing to the variability in clinical manifestations. FAODs are a group of rare metabolic disorders caused by mutations in genes responsible for fatty acid metabolism.
  • Limited Treatment Options
  • Late or Missed Diagnoses


Fatty Acid Oxidation Disorder Segmentation

Type (Long Chain, Short Chain)

The short chain segment is estimated to hold 60% share of the global fatty acid oxidation disorder market in the year 2036. Patient advocacy groups play a pivotal role in driving growth by providing support, resources, and a unified voice for individuals and families affected by SCADD. These organizations contribute to awareness, research funding, and the development of patient-centered initiatives. Patient advocacy groups for SCADD can engage in fundraising activities, awareness campaigns, and educational programs. By fostering collaboration between affected individuals, their families, and the broader healthcare community, these groups amplify the collective effort to address the unique challenges posed by SCADD.

End User (Hospitals, Clinics, Pharmaceutical Companies)

Fatty acid oxidation disorder market from the hospitals segment is expected to garner a significant share in the year 2036. A key growth driver for hospitals is the adoption of a comprehensive patient care model, involving a multidisciplinary approach. This approach ensures that individuals with FAODs receive holistic care that addresses their medical, nutritional, and psychosocial needs. The European Journal of Pediatrics highlights the effectiveness of a multidisciplinary approach in managing metabolic disorders, emphasizing the importance of collaboration among healthcare professionals in diverse specialties. Hospitals can establish specialized metabolic disorder clinics that bring together experts in genetics, nutrition, neurology, and other relevant fields. This collaborative approach ensures that individuals with FAODs receive comprehensive care, including dietary management, medical interventions, and ongoing monitoring.

Our in-depth analysis of the global market includes the following segments:

           Type

  • Long Chain
  • Short Chain

 

   

           End User

  • Hospitals
  • Clinics
  • Pharmaceutical Companies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Fatty Acid Oxidation Disorder Industry - Regional Synopsis

APAC Market Forecast

The fatty acid oxidation disorder market in the Asia Pacific region is projected to hold the largest revenue share of 38% by the end of 2036. The growth of the fatty acid oxidation disorder market in the Asia Pacific is shaped by a multifaceted approach involving increased awareness, genetic testing advancements, government support, pharmaceutical R&D, and patient advocacy. By addressing these growth drivers, the region is poised to make significant strides in improving the diagnosis, treatment, and overall outcomes for individuals affected by FAODs. As these initiatives continue to evolve, the Asia Pacific region is expected to emerge as a key player in the global effort to combat rare metabolic disorders. Patient advocacy groups can collaborate with healthcare professionals and policymakers to ensure that the unique needs of individuals with FAODs are recognized.

North American Market Statistics

The fatty acid oxidation disorder market in the North America region is projected to hold the second largest share during the forecast period. The FAOD market in North America is driven by a comprehensive approach that includes increasing disease awareness, advancements in genetic testing. A primary growth driver in North America is the continuous effort to increase awareness about FAODs among healthcare professionals, patients, and the general public. Educational initiatives and awareness campaigns contribute to early diagnosis and better management of FAODs. According to a report by the National Organization for Rare Disorders (NORD), increased awareness has led to improved diagnostic rates for rare diseases, emphasizing the impact of education in the healthcare sector.

Research Nester
Fatty Acid Oxidation Disorder Market Region
Get more information on this report: Request Free Sample PDF

Companies Dominating the Fatty Acid Oxidation Disorder Landscape

top-features-companies
    • Ultragenyx Pharmaceutical Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Recordati Rare Diseases Inc.
    • Retrophin, Inc.
    • Amicus Therapeutics, Inc.
    • Aeglea BioTherapeutics, Inc.
    • Zogenix, Inc.
    • Homology Medicines, Inc.
    • Censa Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company Limited
    • Regenxbio Inc.

In-the-news

In The News

  • In 2022, Recordati Rare Diseases acquired EUSA Pharma (UK) Ltd, a global specialty pharmaceutical company focused on rare and niche oncology diseases. The acquisition expanded Recordati Rare Diseases' portfolio of rare disease products and pipeline.
  • In 2023, Recordati Rare Diseases announced the acquisition of the trademark and marketing authorization for Italy of the Telefil® brand (tadalafil). This acquisition will expand Recordati Rare Diseases' presence in the Italian market.

Author Credits:  Smruti Ranjan, Rajrani Baghel


  • Report ID: 5403
  • Published Date: Nov 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of fatty acid oxidation disorder is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market Ultragenyx Pharmaceutical Inc., Recordati Rare Diseases Inc., Retrophin, Inc., Amicus Therapeutics, Inc., Aeglea BioTherapeutics, Inc., Zogenix, Inc., and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Fatty Acid Oxidation Disorder Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying